Catalog Advanced Search
Cannabis and the Liver: Update for the HepatologistContains 2 Component(s) Recorded On: 12/12/2019
Webinar hosted by the Clinical Practice Special Interest Group on December 12, 2019.
Use of cannabis is growing in the population with increased interest in potential medicinal use as well as recreational use depending on the jurisdiction. Given this, clinicians need to have an understanding about cannabis and its potential impacts on liver disease. This webinar will provide attendees information about cannabis, its major components (THC/CBD) as well as discuss potential policy implications regarding transplantation. As well, the literature regarding safety and potential benefits/harms will be reviewed in detail. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.
Stephen Congly (Moderator)
Dr. Stephen Congly is a Clinical Assistant Professor at the University of Calgary in the Division of Gastroenterology and Hepatology with a practice consisting of both general and transplant hepatology. He completed his internal medicine and gastroenterology training at the University of Calgary and subsequently a fellowship in Hepatology at the University of Calgary and in Transplant Hepatology at Mayo Clinic, Rochester, MN.
He has a Master of Science in Health Economics, Policy and Management from the London School of Economics and is a member of the O'Brien Institute for Public Health at the University of Calgary. His research interests include health technology assessment, resource utilization, hepatocellular carcinoma and liver transplantation.
Dr. Peltekian is the head of Division of Digestive Care and Endoscopy at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Surgery at Dalhousie University. Since 1995, he has been practicing as a specialist in liver disease and transplantation in Nova Scotia. Over the years, Dr. Peltekian has been frequently recognized for excellence in undergraduate and postgraduate education as well as research. He has over 80 peer-reviewed publications in high impact journals. Over the years, he has held major leadership roles with Chairman and Chief Executive Officer of the Canadian Liver Foundation 2005-2009 and President of the Canadian Association for Study of Liver 2012-2014.
For his volunteer work and contributions to the fight against liver disease, Dr. Peltekian was awarded the Queen Elizabeth II Diamond Jubilee Medal. In 2017, Dr. Peltekian received the CASL Distinguished Service Award for his significant contributions to the practice of Hepatology in Canada. He has been a member of AASLD since 1993.
Leon Schiff State-of-the-Art Lecture: Molecular Pathogenesis and Management of Hepatocellular CarcinomaContains 2 Component(s) Recorded On: 11/12/2019
Leon Schiff State-of-the-Art Lecture: Molecular Pathogenesis and Management of Hepatocellular Carcinoma presented at The Liver Meeting® 2019.
At the 2019 Leon Schiff State-of-the-Art Lecture, our selected speaker will provide a thorough overview of the advances in knowledge of the pathogenesis of hepatocellular carcinoma (HCC). The lecture will explore current data on evidence-based treatment of this disease, including novel molecular therapies and advances in precision oncology.
The Liver Meeting® 2019Contains 39 Product(s)
View on-demand presentations from The Liver Meeting® 2019.
View on-demand presentations from The Liver Meeting® 2019 in Boston. The Liver Meeting® is AASLD’s largest meeting covering a variety of trending topics.
Advances for Practitioners: New AASLD Guidelines: Updated Recommendations and Ongoing Challenges in HCC, PBC and ALDContains 4 Component(s) Recorded On: 11/11/2019
Advances for Practitioners: New AASLD Guidelines: Updated Recommendations and Ongoing Challenges in HCC, PBC and ALD presented at The Liver Meeting® 2019.
AASLD Guideline/Guidance Statements on treating hepatocellular carcinoma (HCC), primary biliary cholangitis (PBC) and alcohol-related liver disease (ALD) are now updated to reflect data published since 2010, when the previous versions were released. At this session, the guidelines’ authors will highlight important changes hepatologists should know and discuss controversial or challenging issues in treating patients with these chronic liver diseases.
Keith D. Lindor
Michael R. Lucey
Emerging Trends Symposium: Microelimination of Viral HepatitisContains 7 Component(s) Recorded On: 11/11/2019
Emerging Trends Symposium: Microelimination of Viral Hepatitis – Positive Use in Organ Transplantation presented at The Liver Meeting® 2019.
HCV-infected organs are now being used for transplantation to HCV-uninfected recipients. This program will review existing data on both liver and non-liver transplantation from HCV-positive donors to HCV-negative recipients and key ethical and practical issues related to HCV-infected donor organs, including whether this should be done only in clinical trials or could be accepted as standard of care.
Jordan J. Feld
Paul Yien Kwo
Global Forum: Alcohol-related Liver Disease: Seeking Local Solutions to A Global ProblemContains 7 Component(s) Recorded On: 11/11/2019
Global Forum: Alcohol-related Liver Disease: Seeking Local Solutions to A Global Problem presented at The Liver Meeting® 2019.
Harmful alcohol use accounts for three million annual global deaths. Experts discuss the global health burden of alcohol-related liver disease (ALD), reporting on ALD’s impact in Africa, Latin America and Asia, region-specific factors that promote or hinder solutions and how forthcoming AASLD guidance on ALD may serve as a template to implement effective prevention and treatment strategies worldwide.
Hailemichael Desalegn Mekonnen
K Rajender Reddy
Shiv Kumar Sarin
Hans Popper Basic Science State-of-the-Art Lecture: Distributed Hepatocytes in Liver Homeostasis and RegenerationContains 2 Component(s) Recorded On: 11/11/2019
Hans Popper Basic Science State-of-the-Art Lecture: Distributed Hepatocytes in Liver Homeostasis and Regeneration presented at The Liver Meeting® 2019.
The annual Hans Popper Lecture clarifies exciting new findings on cellular renewal mechanisms in liver disease and liver cancer. A subset of hepatocytes with high levels of telomerase are distributed throughout the liver lobule, serving to renew the organ during homeostasis and in response to injury. Learn how genetic ablation of these hepatocytes results in scarring and defective regenrative responses.
Adrian Di Bisceglie